In 2017, the global market for veterinary therapeutics was valued at US$ 35,005.2 Mn and is projected to reach a value of US$ 54,968.3 Mn by 2025. Furthermore, the report predicts the global market to expand at a CAGR of 5.8% during the forecast period.
Segmentation:
By Animal Type
- Companion
- Livestock
By Product Type
- Medicated Feed Additives
- Drugs
- Vaccine
By Distribution Channels
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies & Drug Stores
By Route of Administration
- Oral
- Parenteral
- Topical
Some of the Main Key Players Covered in the Report:
- Merck Animal Health
- Zoetis Inc.
- Elanco
- Merial
- Bayer Pharmaceuticals
- Bayer
- Boehringer Ingelheim
- CEVA LogisticsVetoquinol S.A.
- IDEXX
- Virbac
Focus on Expanding Product Portfolio May Offer Promising Growth Opportunities
Some of the leading players operational in the global market for veterinary therapeutics are Zoetis, Intervet Inc., Vetoquinol S.A., Elanco, Merial, IDEXX Laboratories, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Virbac, and Ceva. In 2017, Zoetis was the leading player in the global market with the presence of strong product portfolio. One of the chief strategies adopted by companies is strengthening their product portfolio by introducing new products. This is projected to generate huge growth opportunities for the global veterinary therapeutics market during the forecast period between 2017 and 2025.
More Trending Topics From Fortune Business [email protected]
